Published in Medscape J Med on December 31, 2008
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med (2003) 12.71
Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med (2005) 4.97
Epidemiology of restless legs symptoms in adults. Arch Intern Med (2000) 3.68
Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med (2004) 3.49
Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology (2002) 2.53
Nocturnal blood pressure changes in patients with restless legs syndrome. Neurology (2007) 2.15
Iron and the restless legs syndrome. Sleep (1998) 1.87
Restless legs syndrome and polyneuropathy. Mov Disord (2006) 1.68
Rise of blood pressure with periodic limb movements in sleep and wakefulness. Clin Neurophysiol (2007) 1.62
Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol (2001) 1.53
Successful treatment of recalcitrant restless legs syndrome with botulinum toxin type-A. J Clin Sleep Med (2006) 1.51
Restless legs syndrome and pregnancy. Neurology (2004) 1.40
An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep (2004) 1.34
Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet (2001) 1.30
Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep (1996) 1.23
An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology (2000) 1.22
A questionnaire study of 138 patients with restless legs syndrome: the 'Night-Walkers' survey. Neurology (1996) 1.21
Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol (2007) 1.20
Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology (2003) 1.16
A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis (2004) 1.15
The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med (2004) 1.14
Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs (2004) 1.12
Augmentation as a treatment complication of restless legs syndrome: concept and management. Mov Disord (2007) 1.10
New paradigms in the treatment of restless legs syndrome. Neurology (2005) 1.04
Dopaminergic therapy in children with restless legs/periodic limb movements in sleep and ADHD. Dopaminergic Therapy Study Group. Pediatr Neurol (2000) 1.01
Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep (1993) 1.00
A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med (2008) 0.99
Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med (2000) 0.98
Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord (2001) 0.97
Restless legs syndrome in hemodialysis patients: health-related quality of life and laboratory data analysis. Clin Nephrol (2006) 0.96
Gabapentin versus levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study. Ren Fail (2004) 0.95
Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. Sleep Med (2005) 0.93
A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol (2000) 0.92
Restless legs syndrome is frequently overlooked in patients being evaluated for polyneuropathies. Eur J Neurol (2007) 0.89
Restless legs syndrome in lung transplant recipients. J Heart Lung Transplant (2007) 0.89
Long-term course of restless legs syndrome in dialysis patients after kidney transplantation. Mov Disord (2002) 0.89
Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam. Eur Neuropsychopharmacol (2001) 0.87
Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol Scand (2007) 0.87
Treatment of restless legs syndrome with tramadol: an open study. J Clin Psychiatry (1999) 0.84
Restless legs syndrome in hemodialysis patients: association with calcium antagonists. A preliminary report. Eur Neurol (2007) 0.83
Relationship of periodic leg movements and severity of restless legs syndrome: a study in unmedicated and medicated patients. Clin Neurophysiol (2007) 0.82
Restless legs symptoms without periodic limb movements in sleep and without response to dopaminergic agents: a restless legs-like syndrome? Eur J Neurol (2007) 0.81
Restless legs syndrome associated with primary hyperparathyroidism. Sleep Med (2005) 0.78
Periodic leg movements in sleep with restless legs syndrome: effect of clonazepam treatment. Jpn J Psychiatry Neurol (1992) 0.77
Double-blind evaluation of clonazepam on periodic leg movements in sleep. J Neurol Neurosurg Psychiatry (1987) 0.77
Response to Clinical Corners case (Sleep Medicine 6/2: 83-4): Pregnancy associated with daytime sleepiness and nighttime restlessness. Sleep Med (2005) 0.77
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet (2010) 4.47
Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Ann Neurol (2007) 1.92
Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol (2008) 1.89
Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord (2008) 1.61
SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol (2010) 1.54
Genetic association between alpha-synuclein and idiopathic Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet (2008) 1.50
Exploring gene-environment interactions in Parkinson's disease. Hum Genet (2008) 1.43
Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Mov Disord (2006) 1.28
LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet (2006) 1.26
Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch Neurol (2006) 1.09
Movement disorders associated with aripiprazole use: a case series. Int J Neurosci (2009) 0.95
Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease. Eur J Neurol (2007) 0.87
Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. Parkinsonism Relat Disord (2008) 0.86
DBH -1021C-->T does not modify risk or age at onset in Parkinson's disease. Ann Neurol (2007) 0.83
Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease. Genet Test (2006) 0.81
Gabapentin enacarbil - clinical efficacy in restless legs syndrome. Neuropsychiatr Dis Treat (2010) 0.81
Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment. Neurologist (2011) 0.75
Mydriasis in a Parkinson disease patient on low-dose carbidopa/levodopa. Mov Disord (2013) 0.75